ArrowMark Colorado Holdings’s Talis Biomedical Corporation Common Stock TLIS Stock Holding History

ArrowMark Colorado Holdings’s Portfolio TLIS Stock Details TLIS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-31,924	Closed	-$235K	–	317
2023 Q1	$235K	Sell	31,924 -45,344	-59%	-$385K	﹤0.01%	294
2022 Q4	$516K	Sell	77,268 -2,496	-3%	-$21.9K	0.01%	268
2022 Q3	$816K	Sell	79,764 -108,241	-58%	-$1.37M	0.01%	274
2022 Q2	$2.29M	Sell	188,005 -61,011	-25%	-$965K	0.03%	244
2022 Q1	$5.27M	Sell	249,016 -78,667	-24%	-$2.72M	0.05%	241
2021 Q4	$19.7M	Sell	327,683 -65,242	-17%	-$4.88M	0.16%	126
2021 Q3	$36.8M	Buy	392,925 +1,463	+0.4%	+$195K	0.29%	94
2021 Q2	$32.7M	Sell	391,462 -8,669	-2%	-$1.47M	0.25%	103
2021 Q1	$77.1M	Buy	+400,131	New	+$99.8M	0.58%	55

Other funds holding TLIS

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ArrowMark Colorado Holdings's TLIS Position: Q2 2023 in Review

ArrowMark Colorado Holdings sold out of Talis Biomedical Corporation Common Stock (TLIS) in Q2 2023, closing a stake of 31,924 shares — an estimated $235K sold.

ArrowMark Colorado Holdings first reported a position in TLIS in Q1 2021 and held it in 9 quarters. The position peaked at $77.1M in Q1 2021. 22 funds tracked by Wall St. Rank hold TLIS as of Q2 2023.

ArrowMark Colorado Holdings reported no remaining Talis Biomedical Corporation Common Stock position as of Q2 2023 after selling out during the quarter.
ArrowMark Colorado Holdings sold 31,924 Talis Biomedical Corporation Common Stock shares in Q2 2023, an estimated $235K.
ArrowMark Colorado Holdings first reported a position in Talis Biomedical Corporation Common Stock in Q1 2021 and held it in 9 quarters.
ArrowMark Colorado Holdings's Talis Biomedical Corporation Common Stock position peaked at $77.1M in Q1 2021.
22 funds tracked by Wall St. Rank held Talis Biomedical Corporation Common Stock as of Q2 2023.

Based on ArrowMark Colorado Holdings's 13F filing for Q2 2023, filed 14 Aug 2023.